Completeness of prescription information in US commercial claims databases
Version of Record online: 21 MAY 2013
Copyright © 2013 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 22, Issue 8, pages 899–906, August 2013
How to Cite
Lauffenburger, J. C., Balasubramanian, A., Farley, J. F., Critchlow, C. W., O'Malley, C. D., Roth, M. T., Pate, V. and Brookhart, M. A. (2013), Completeness of prescription information in US commercial claims databases. Pharmacoepidem. Drug Safe., 22: 899–906. doi: 10.1002/pds.3458
- Issue online: 21 JUL 2013
- Version of Record online: 21 MAY 2013
- Manuscript Accepted: 17 APR 2013
- Manuscript Revised: 15 MAR 2013
- Manuscript Received: 26 OCT 2012
- generic drugs;
- claims data;
- data quality;
Pharmacy commercial claims databases are widely used for pharmacoepidemiologic research. However, concerns have been raised that these databases may not fully capture claims for generic medications as a result of patients filling outside the context of their insurance. This has implications for many research activities and quality improvement programs. We sought to estimate the percentage of missing prescriptions in US commercial claims data using a novel design.
Using a large US commercial insurance database, we examined the completeness of warfarin prescription claims among patients with atrial fibrillation receiving regular medical follow-up and testing to manage warfarin dosing. We examined 14 different 6-month cross sections. Each cross section was treated independently to identify patients with at least two outpatient diagnoses of atrial fibrillation, two international normalized ratio tests, and one pharmacy claim. Trends in the percentage of patients with prescription claims for generic and branded warfarin were compared by year and 6-month periods using chi-square tests and generalized linear models adjusting for patient characteristics.
Out of 111 170 patients, the percentage of patients with any warfarin drug decreased slightly from 91.7% (95% CI: 91.0, 92.4) in early 2003 to 87.1% (95% CI: 86.7–87.6) in late 2009 (χ2 = 93.8, p < 0.0001). Over the same interval, the proportion of patients with generic warfarin exposure appearing increased significantly, whereas the proportion of patients with branded warfarin exposure decreased significantly.
Our study supports the possibility that some prescriptions may not be captured in US commercial insurance databases. Copyright © 2013 John Wiley & Sons, Ltd.